Pushing the boundaries of regenerative medicine

August 8, 2023

The collaborators have been awarded £800,000 of Innovate UK Biomedical Catalyst funding to develop an integrated and scalable platform to manufacture allogeneic induced pluripotent stem cell (iPSC) derived immunotherapies.

April 25, 2023

Plasticell Ltd, a developer of stem cell technologies and advanced therapies, has announced today that it has entered into a strategic collaboration with Singapore-based LambdaGen.

June 14, 2022

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has today announced that it has engaged Veritas Corporation of Tokyo as the exclusive distributor for all of its services and products, including CombiCult®, in Japan.

May 28, 2021

Plasticell, the biotechnology company specialising in cell and gene therapy research, has completed an equity financing round raising a total of £1.4 million.

February 25, 2020

Plasticell, a developer of stem cell technologies and advanced therapies, has announced it has been awarded Biomedical Catalyst funding to perform a project valued at 594,210 GBP.

September 4, 2018

Plasticell will deploy its combinatorial stem cell screening platform, CombiCult®, to develop technologies for the conversion of pluripotent stem cells into platelets that promote tissue recovery and regeneration.

August 31, 2018

Plasticell Ltd, in partnership with the Advanced Stem Cell Training Network (ASCTN), secures over €3.7M in EU funding to develop advanced cellular models for neurological disorders, including Parkinson’s and Huntington’s diseases.

June 26, 2018

UK’s innovation agency provides funding to develop advanced technologies for the manufacturing of autologous ex vivo gene therapies.

December 4, 2017

Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers.

October 17, 2017

Plasticell, the bio technology company, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®.

April 19, 2017

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, today announced it has partnered with Kings College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells.

April 13, 2017

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, today announced it has secured Biomedical Catalyst funding of over 920,000 GBP from Innovate UK.

March 28, 2017

Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.

February 7, 2017

Plasticell founder named “Best CEO in the Stem Cell industry” by European CEO magazine

November 22, 2016

Plasticell, a pioneer in stem cell therapy, unveils groundbreaking research in Stem Cells and Development, showcasing their innovative technology for expanding therapeutic stem cells in cord blood.

November 4, 2016

Plasticell secures £1.32M to advance stem cell therapies, including hematopoietic stem cell expansion. Supported by an Innovate UK grant, their CombiCult® technology drives progress towards clinical development.

September 19, 2016

Plasticell and CellSpring are developing tissue models using 3D Bloom Biopolymer seeded with hMSCs that are subsequently differentiated to bone, cartilage and brown/white fat tissue using CombiCult-derived differentiation media.

August 2, 2016

collaboration agreement with the National University of Ireland, Galway (NUI Galway) focused on methods of eradicating cancer stem cells.

April 21, 2016

Plasticell is pleased to announce it has been awarded the 2016 Queen’s Award for Enterprise in Innovation.

March 29, 2016

the signing of a collaboration agreement with Sphere Fluidics, a company specializing in single cell encapsulation and screening.

February 23, 2016

The two companies will work together to discover plant-based products that enhance the metabolic function of brown adipose tissue (BAT) – also known as ‘brown fat’.

June 15, 2015

Plasticell, the regenerative medicine company utilising its award-winning combinatorial technologies for stem cell research and in developing cell therapies, has recruited Dr Aaron Chuang to its executive management team in the role of Chief Scientific Officer (CSO).

February 5, 2015

Plasticell has announced that Innovate UK has made a further investment in a therapeutic programme utilising CombiCult®, the high throughput stem cell technology designed to solve bottlenecks in regenerative medicine development

September 25, 2014

Plasticell Limited announced today the publication of peer-reviewed scientific research that demonstrates how the company’s proprietary ‘Combinatorial Cell Culture™‘ (CombiCult®) technology allows scientists to perform and compare 10,000 embryonic stem cell differentiation experiments in parallel.

March 25, 2014

February 24, 2014

Plasticell, the biotechnology company specializing in stem cell differentiation, has today announced that it has signed a collaboration agreement with JCR Pharmaceuticals Co., Ltd. of Ashiya, Hyogo Pref., Japan, to discover custom stem cell culture media using its award-winning combinatorial stem cell technology, CombiCult®.

November 11, 2013

Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that a further family of patents, offering additional protection of its proprietary cell culture technology, Combinatorial Cell Culture™ (CombiCult®), have been granted by the US Patent Office, European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore.

June 10, 2013

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is pleased to welcome regenerative medicine companies Plasticell Ltd and Progenitor Labs as tenants. Progenitor Labs is a drug discovery spin-off from Plasticell and recently received £4m in funding from SR One, the corporate venture arm of GlaxoSmithKline (GSK). Cell therapy and regenerative medicine is a focus of SBC’s open innovation activities, and these two new tenants are expected to play a major role in the incubator’s growing network in this area.

May 9, 2013

EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, and Plasticell of London, UK, today announced the availability of OsteoMAX-XF™, the first fully defined, xeno-free human mesenchymal stem cell differentiation medium for the differentiation of mesenchymal stem cells into osteocytes. Mineralization can be detected in less than one week, whereas competing products that contain serum require approximately 21 days to produce similar levels of bone formation.

March 11, 2013

Investment from SR One, GlaxoSmithKline’s Corporate Venture Fund, will fund company’s programme to discover small molecule drugs that regenerate specific tissues of the body.Progenitor Labs Ltd (Progenitor) has announced that it has raised £4 million ($5.8million) in seed financing from SR One’s UK Fund.

August 14, 2012

Plasticell, the UK stem cell differentiation specialist has licensed EMD Millipore, the Life Science Division of Merck KGaA, to distribute a superior, single-application osteogenic medium discovered using the award winning, massively parallel combinatorial screening system, CombiCult®.

June 14, 2012

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has today announced that it has engaged Veritas Corporation of Tokyo as the exclusive distributor for all of its services and products, including CombiCult®, in Japan.

February 13, 2012

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, today announced that patents for its combinatorial cell culture platform technology, CombiCult™, have been granted in the USA and Japan.

January 10, 2012

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced that the Technology Strategy Board has funded a research consortium comprising of Plasticell, Pfizer (Neusentis) and the University of Sheffield, led by Cellzome. The project will develop methods of characterizing stem cells through protein fingerprints predictive of changes in stem cell behaviour.

December 6, 2011

Plasticell has announced that the Technology Strategy Board has made a further investment in the Company’s flagship technology, CombiCult™, the high throughput technology designed to solve the major bottleneck in stem cell research and development.

August 3, 2011

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced the successful completion of a collaboration with Stemnion, Inc. (Pittsburgh, PA), a US biotechnology company focused on the applications of stem cells derived from human placentas.

July 23, 2011

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has won the prestigious R&D 100 Award for its CombiCult™v2.0 system. The CombiCult™ platform is a high-throughput combinatorial screening technology that allows scientists to discover optimal stem cell differentiation protocols in record time, revolutionizing stem cell research and opening new avenues of discovery.

April 13, 2011

Plasticell Ltd, the biotechnology company developing high throughput stem cell technologies, has announced today that following its recent £3.5m financing, it has undergone a strategic re-structuring to enable the Company to focus on its award winning CombiCult™ technology for stem cell differentiation. Consequently, Plasticell Ltd has demerged its regenerative drug discovery unit into a newly established company, Progenitor Labs Limited.

January 31, 2011

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced it has completed a two-part equity financing, raising a total of £3.5 million from new and existing investors.

November 29, 2010

Collaboration to produce novel turnkey solution for stem cell researchPlasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced the signing of a collaboration agreement with Sigma-Aldrich, a leading provider of technologies and reagents to the life science research market.

November 8, 2010

technologies in stem cell research, has announced signing of a collaboration agreement with the biopharmaceutical company, UCB.Under the terms of the agreement, UCB will supply Plasticell with drug compound libraries with known biological targets. Plasticell will screen these using its award-winning CombiCult technology to discover new cell signaling pathways involved in stem cell biology, including tissue regeneration.

March 12, 2009

London, 12 March 2009 … Research announced today by Plasticell, a leading UK regenerative medicine biotech company, shows how embryonic stem cells can be used to discover novel small molecules capable of encouraging the body to regenerate, potentially paving the way for the development of drugs to repair organs damaged by disease or ageing.

January 15, 2009

London, UK, 15 January 2009. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, today announced that it is funding industrial collaborative projects in two separate laboratories based in University College London (UCL).

October 1, 2008

London, UK, 1 October 2008. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced it has received further funding from the Technology Strategy Board (TSB; formerly part of DTI) to apply its technologies towards developing a novel cell therapy designed to stimulate and sustain tissue regeneration.

August 1, 2008

London, UK, 1 August 2008. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced the publication of a book chapter which presents the case for combinatorial methods in stem cell research.

April 2, 2008

London, UK, 2 April 2008. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has appointed Professor Tony Cass to its Scientific Advisory Board.

February 13, 2008

London, UK, 13 February 2008. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has entered into an agreement with King’s College London (London, UK) to exploit and market two human embryonic stem cell (hESC) lines.

January 14, 2008

London, UK, 14 January 2008. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has entered into an agreement with Axordia Ltd (Sheffield, UK) to exploit and market a panel of six human embryonic stem cell (hESC) lines.

November 13, 2007

London, UK, 13 November 2007. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that Dr Yen Choo, the company’s Chief Executive, has been appointed to the Steering Committee for the UK Stem Cell Bank and for the Use of Stem Cell Lines.

October 9, 2007

London, UK, 9 October 2007. Plasticell Ltd is delighted to note that Sir Martin Evans, a founding member of the company’s Scientific Advisory Board, has been awarded this year’s Nobel Prize in Physiology or Medicine together with Mario Capecchi and Oliver Smithies for their discoveries of “principles for introducing specific gene modifications in mice by the use of embryonic stem cells”.

September 24, 2007

London, UK, 24 September 2007. Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has entered into an agreement with Hamilton Company, a worldwide leader in robotic liquid handling devices and laboratory automation, to automate Plasticell’s Combinatorial Cell Culture™ technology for the determination of optimal protocols to direct stem cell differentiation.

January 25, 2007

London, UK, 25 January 2007. Plasticell Ltd, the UK biotechnology company developing drugs to regenerate tissues of the body, announced today that it has secured a £1.1m Technology Programme grant from the Department of Trade & Industry (DTI), to support a three year collaborative research and development project entitled “A technology to ensure optimum cell performance for regenerative medicine”.

January 2, 2007

London, UK, 2 Jan 2007. Plasticell Ltd, the UK biotechnology company developing drugs to regenerate tissues of the body, has relocated its offices and laboratories to the newly opened Imperial BioIncubator, a facility managed by Imperial Innovations and sited at Imperial College London’s South Kensington campus.

May 22, 2006

London UK, 22 May 2006. Plasticell Ltd, the UK biotechnology company developing drugs to regenerate tissues of the body, has appointed Christopher Adam to its board. He will assist the company with corporate and product development strategies.

June 9, 2004

London, UK, 9 June 2004. Plasticell Ltd, a seed stage biotechnology company developing high throughput technology for stem cell research, today announced it has closed its first equity financing round after securing over £0.5m from angel investors including a syndicate comprising private clients of the financial services group Williams de Broë.

December 1, 2002

London, UK, 1 December 2002. A UK-based, start-up biotechnology company, Plasticell Ltd, has been created to commercialise an innovative high throughput technology for cell biology.